Stocktoria
Outset Medical, Inc. OM
Outset Medical, Inc. (OM) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $119.5M at a -68.3% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -3.24 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.806 |
| Retained earnings / assets | -4.429 |
| EBIT / assets | -0.252 |
| Equity / liabilities | 0.923 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| OM | Outset Medical, Inc. | 6/9 | -9.87 | — | +5.1% |
| BLFS | BIOLIFE SOLUTIONS INC | 6/9 | 10.32 | — | +28.9% |
| VASO | VASO Corp | 6/9 | 0.72 | 21.3 | +2.7% |
| CBLL | Ceribell, Inc. | 3/9 | 3.97 | — | +36.1% |
| FOCL | EDAP TMS SA | 3/9 | -5.4 | — | +1.6% |
| ELMD | Electromed, Inc. | 6/9 | 10.99 | 46.4 | +17% |
| IRIX | IRIDEX CORP | 4/9 | -8.01 | — | +8.2% |
About Outset Medical, Inc.
Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company provides Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also offers Tablo Data Ecosystem, including TabloHub, a consumer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
FAQ
Is OM financially healthy?
Outset Medical, Inc.'s Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does OM pay a dividend?
No, Outset Medical, Inc. does not currently pay a dividend.
How profitable is OM?
In FY2025, Outset Medical, Inc. had a net margin of -68.3% and a return on equity of -64.3%.
What is the analyst price target for OM?
The average Wall-Street price target for Outset Medical, Inc. is $7.67, about 70.4% above the recent price, from 3 analysts (consensus: buy).
Is OM a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Outset Medical, Inc.: a Piotroski F-score of 6/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.